

1 **Appendix D: Constrained Optimization Modeling**

2 **Introduction**

3 Constrained optimization (CO) modeling has been applied for over 100 years. It was initially
4 used to improve work efficiency in various industrial settings. It is currently applied in
5 healthcare for very diverse purposes, including for capacity management, clinical decision
6 making, and optimal allocation of resources (Crown et al., 2017).

7 The focus in this appendix is on using CO modeling to determine whether new vaccination
8 programs are cost-efficient which means obtaining the best outcome for the limited
9 resources/cost available. The model therefore provides information on how to optimize health
10 outcomes with the different intervention options and the different constraints, the latter
11 mainly on budget and logistics. CO is used to derive the optimal levels of each available
12 intervention to be selected.

13 Papers on the use of CO for decisions about communicable disease programs were first
14 published in the 1970s (Sanders, 1971; Sethi, 1974) and for allocating healthcare resources
15 across all diseases by the end of the 1990s (Stinnett et al., 1996; Petrou et al., 2000). These
16 methods were used when the budget, intervention types, and the desired outcomes for
17 specific health and healthcare domains like diabetes, AIDS, cancer, for instance, could be
18 clearly delineated.

19 For CO, a distinction must be made between model construction and the analysis method
20 used to evaluate the model.

21 The basis for the model construction is mathematical programming that assembles different
22 components (variables) among which relationships are found. These relationships are
23 expressed as mathematical equations that quantify the problem through input and output
24 variables and the parameter values selected. The results of the model (the output) can be
25 validated using observational data to test the accuracy of the model construct. Four elements
26 are needed to develop the mathematical construct:

- 27 1. The objective to be optimized must be presented as a maximization or minimization
28 value of an output variable.
- 29 2. The decision variables selected must influence the value of the output variable.
- 30 3. The objective function (relationship between the decision variables and the objective)
31 must comply with a set of constraints, such as budget limits, logistic constraints, or
32 both.
- 33 4. A list of parameter values must quantify the relationship between the decision
34 variables and the objective and constraints.

35 Regarding the analysis method for CO, the simplex method is one of the most commonly
36 used in very diverse industries, such as agriculture, forest management, fisheries, information
37 technology, and healthcare (Dixit, 1990; Buongiorno et al., 2003). It should, however, be
38 noted that many optimizing real world problems may be too complex to use the simplex
39 method. Some examples of the more complex models include having multiple objectives
40 instead of one, consideration of a very large number of decision variables, with many
41 constraints, or having a nonlinear relationship between the decision variables and the
42 objective or objectives and constraints that vary over time. Because those more advanced
43 problems, where linear functions cannot be derived for all the relationships in the
44 mathematical model, cannot be solved with the simplex methods, heuristic methods (neural

45 networks, genetic algorithms, simulated annealing, etc) are then used. With today's
46 computing power, new software to search for the best allocations to these problems exists.
47 However, problems can grow in size such that solving is computationally very exhaustive.
48 Consultation with experts is an absolute prerequisite before engaging in such analysis
49 methods.

50 A good general reference is *Optimization Modeling: A Practical Approach* (Sarker and
51 Newton 2008). A recently published overview on the application of CO in healthcare has
52 been prepared by the International Society for Pharmacoeconomics and Outcomes Research
53 Task Force on Constrained Optimization Methods (Crown et al., 2017).

54 CO has also been used to identify the best approaches for managing certain infectious disease
55 problems having access to different intervention types. For instance, it was used to identify
56 the most effective combination of interventions to prevent malaria, such as bed net use, in-
57 house insecticide spraying, preventive drug use, treatment, and vaccination (Walker et al.,
58 2016). CO has also been applied to determine the best combination of screening and
59 vaccination to prevent human papillomavirus infection and cervical cancer with (Demarteau
60 et al., 2012, 2014).

61 An approach closely related to CO to set priorities for developing and introducing new
62 vaccination programs is the Strategic Multi-Attribute Ranking Tool developed by the
63 Institute of Medicine in the United States (Madhavan et al., 2012, 2013; IOM, 2012).
64 Weniger et al. (1998) and Becker and Starczak (1997) previously used a similar approach.

65 A more recent example of the use of CO modeling to make decisions about new vaccination
66 programs is the Portfolio Management of Vaccines model (Standaert et al. 2017). This model
67 helps setting priorities for introducing a vaccination program when different vaccines are
68 available in the market but no implementation plan is in place because of local constraints.
69 The constraints might be budgetary or related to feasibility and logistics, such as labor force
70 availability, cold-chain maintenance, or transportation or delivery facilities. The model ranks
71 the introduction of different new vaccination programs in a multiyear budget plan to
72 maximize one or more outcome measures (e.g. QALYs gained, hospitalizations or medical
73 visits avoided, or medical costs or mortality rates reduced) of interest to the decision maker.

74 **Decision Problem**

75 CO involves the construction of an optimization model and the selection of an optimization
76 analysis method. The optimization model requires an objective function that is presented in a
77 mathematical equation relating how the disease of interest is managed through different
78 interventions in the presence of specific constraints (Earnshaw et al., 2003). The analysis
79 method predicts the change in the outcome of the objective function by searching for the best
80 allocation among the possible interventions while considering the constraints using an
81 optimization algorithm (see section on Model Structure and Assumptions).

82 A simple example of the use of CO is the knapsack problem (Sarker and Newton, 2008). A
83 decision needs to be made about which items to put in a knapsack but the weight of what can
84 be carried has a limit. The selection of items to be in the knapsack is also based on a criteria
85 of being most useful expressed through a value index. Each item can therefore be chosen
86 through its weight and specific value index. The optimization algorithm searches for the
87 highest value to be transported in the knapsack by selecting the best combination of items
88 within the maximum weight affordable for the knapsack as a constraint.

89 In the context of disease management, the knapsack's weight limit is analogous to the budget
90 limit for managing a disease, and the items to place in the knapsack are the intervention
91 options available. Each intervention has a different cost and impact (value index) on the
92 diseases. The objective function is to maximize the reduction in disease incidence within the
93 budget constraint by selecting and combining interventions in a way that maximizes the
94 impact.

95 Another type of decision problem can also be addressed with this model. It is to identify the
96 minimum budget required to achieve a certain impact goal, such as reducing a disease's
97 incidence by 35% within 5 years using a combination of interventions that has the lowest
98 overall budget.

99 **Perspective**

100 Applying CO to a vaccination program is most useful from the perspective of a budget holder
101 as decision maker who will select a mix of interventions to address a specific healthcare
102 problem, such as all infectious diseases or a specific infectious disease. The budget holder's
103 perspective might be limited to healthcare costs and disease prevalence, or it might include a
104 broader range of inputs, outputs, and constraints to make it more comprehensive. For
105 example, the ministry of finance might want to learn about a vaccine's ability to reduce work
106 absenteeism rates while optimizing tax revenues.

107 **Time Horizon**

108 At least two-time horizons should be considered for CO. One depends on the disease model
109 used to simulate its natural history with the impact a new intervention under study will have.
110 The time horizon is that period during which a person remains at risk and during which the
111 selected intervention will influence that risk. For example, many infectious diseases that can
112 be prevented with vaccines in children are health risks for the first 5 years of life. Therefore,
113 the time horizon of the CO model such that the outcome measure can quantify health gains
114 through the selected interventions should include at least the first 5 years of life.

115 The other time horizon to assess is the one linked to the application of specific constraints.
116 For example, a budget holder could have a fixed budget over a number of years to fund the
117 new intervention. The time horizon of the analysis for that budget holder is then defined by
118 the years the budget is available.

119 **Model Structure and Assumptions**

120 The structure of a constrained optimization model should be built in three steps, described
121 below.

122 The first step is to express or translate the decision problem into an optimization task.
123 Specifically, the outcome measure to be maximized or minimized needs to be identified for
124 the diseases under study through specific interventions (= the decision variables). The type of
125 outcome measures can be, for instance, QALYs gained, DALYs avoided, mortality reduction,
126 cases avoided, or costs spent on preventing and/or treating the disease. The decision variables
127 are the different interventions to be selected to achieve the objective. They may include
128 treatment, screening + treatment, vaccination, etc. The optimal selection of these
129 interventions is determined based on their contribution to the objective being optimized and
130 the constraints on these interventions included in the decision problem.

131 In a second step, the decision problem is expressed as a mathematical function (objective
 132 function). The outcome measure to be optimized (single objective) is related to the different
 133 decision variables considered. Sometimes, more than one objective can be optimized within
 134 the same model. For example, a multi-objective model might aim to maximize the number of
 135 QALYs gained and avoided hospitalizations, whereas a single-objective model might aim to
 136 maximize the number of QALYs gained only or avoided hospitalizations only.

137 Constraints on the decision variables or other jurisdiction-specific inputs that the objective
 138 function must satisfy should be listed and defined in the third step. Examples of constraints
 139 are available budget, observed treatment or prevention adherence rates, and feasibility or
 140 minimally acceptable rates of participation in a medical intervention. Constraints can be
 141 expressed as equality/inequality functions (e.g., equal (=), less than or equal to (\leq), or greater
 142 than or equal to (\geq) a certain predefined value). Constraints may also be mathematically
 143 presented as “either-or” or “if-then” statements. As an example a budget holder is interested
 144 in funding health care interventions such that the maximum number of QALYs is accrued.
 145 The number of interventions given is no more than the number of individuals in the
 146 population who are eligible for the interventions. The budget holder has a limited budget to
 147 spend. To construct the model, first, we define the variables and parameters. For this
 148 example, we have:

149 Decision variables:

150 x_i = number of intervention i 's to be funded where $i = 1$ to n interventions

151 Parameters:

152 p_i = QALYs accrued when funding one unit of intervention i where $i = 1$ to n
 153 interventions

154 c_i = cost of one unit of intervention i where $i = 1$ to n interventions

155 B = budget holder's budget

156 P = population eligible for the interventions

157 Table D1 lists how the model structure could be developed.

158 Table D1: Defining the model structure of a constrained optimization model.

Step	Mathematical formulation	Description of equations
Objective function	$\text{Max } \sum_i^n p_i x_i$	Maximize the number of QALYs accrued
Intervention selection constraint	$x_1 + x_2 + x_3 + x_4 \dots + x_n \leq P$	Number of interventions selected can be no larger than the number of individuals eligible for the interventions
Budget constraint	$c_1 x_1 + c_2 x_2 + c_3 x_3 + c_4 x_4 \dots + c_n x_n \leq B$	Funded interventions can cost no more than budget B
Decision variables	$0 \leq x_1, x_2, x_3, x_4 \dots x_n$	Number of individuals receiving each intervention must be 0 or greater
Parameter values	$c_1, c_2, c_3, c_4 \dots c_n, p_1, p_2, p_3, p_4 \dots p_n \geq 0$	Cost of and QALYs able to be accrued by each intervention unit must be 0 or greater

159 The example above is structured as a continuous linear, constrained optimization problem.
 160 These forms are the most straightforward and easiest to solve. However, the real world may
 161 not occur in this format. The objective function and/or constraints could be
 162 nonlinear/dynamic and the decision variable might need to be restricted to integer values. In
 163 these cases, the formulations are the same. It is the analysis method used to find the optimal
 164 allocation that will be more complex.

165 **Comparators**

166 In CO modeling, no comparison is made. The exercise finds the best combination of
167 interventions to optimize a health objective given the constraints. However, a budget holder
168 might use a CO analysis to determine whether and how much the selected optimal mix is
169 superior to any other alternative that does not apply the optimization algorithms. The
170 comparator could then be a mix of interventions randomly chosen versus those chosen using
171 the optimization exercise.

172 Sometimes, new interventions can only be introduced one at a time because of budget limits.
173 If so, the optimization exercise can result in a ranking of interventions to introduce
174 sequentially in a way that allows health objectives to be achieved most efficiently within pre-
175 specified timeframes. The interesting comparator could then be the introduction of
176 interventions not following the optimization process. They are introduced in a random
177 fashion or an order determined by the decision maker or budget holder without considering
178 optimization concerns.

179 **Data Requirements and Sources**

180 Many of the data required for CO are the same as for any other economic analysis of a new
181 vaccination program (see Appendix C and E). Specifically, data must be collected on
182 resource use, cost of current and new interventions as well as the disease(s) outcomes with
183 each intervention.

184 CO differs from cost-effectiveness analysis and fiscal health modeling as it has a list of
185 constraints that the analysis process needs to take into account. The constraints to include will
186 come from budget holders as decision makers, or operational managers taking care of the
187 logistic consequences of the program such as maintaining a cold chain, developing
188 stockpiling, ensuring feasible levels of each intervention based on resource and behavior
189 constraints among others.

190 Input data about disease outcomes with the alternative interventions for CO models that are
191 used to address infectious disease problems can come from separate disease models
192 developed independently of the CO model. This allows the analyst to avoid complexities in
193 finding the optimal solutions based on dynamic disease models that capture indirect effects of
194 vaccination programs. Including the dynamic disease models in the objective function
195 directly could make it difficult to find an exact solution for the optimum combination of
196 interventions. Running the dynamic model and the CO model in parallel is a more elegant
197 way to obtain results while keeping the optimization analysis method simple.

198 **Outcome Measures**

199 CO can use single or composite measures to be maximized or minimized, depending on how
200 the problem is formulated. Single measures that are frequently used include life expectancy
201 gains; mortality reductions; avoided hospitalizations, medical visits, or disease cases;
202 reductions in disease-related costs; and maximized net present value. Composite measures
203 that can be selected include QALYs and combined endpoints, such as reductions in
204 hospitalization and mortality rates. For a composite endpoint, each component should be
205 weighted by a specific factor. The process to identify the weighting should be well defined
206 and clearly reported.

207 **Discounting**

208 No recommendation for discounting in CO for health care has been issued to date. However,
209 whether to use discounting is likely to depend on the outcome measure selected in the
210 objective function and the time horizon for the budget analysis (i.e. whether it is short term or
211 extended). For example, discounting is needed when the net present value of a new
212 vaccination program with a longtime horizon is optimized. If the analysis focuses on a time
213 horizon of no more than 3 years and the outcomes occur within this period, discounting
214 should not be used. The literature on CO in healthcare, including on the Strategic Multi-
215 Attribute Ranking Tool for vaccines already mentioned in the introduction, shows that a
216 discount rate for clinical outcomes and for cost of 3% per year is used for studies with a long
217 time horizon with sensitivity analyses performed for discount rates between 0% to 5%
218 (Madhavan et al., 2012).

219 **Analysis Method**

220 Many CO models use linear programming to define the objective function if the problem can
221 be expressed as a continuous, linear function with constraints that are also expressed as linear
222 functions. The simplex method can then be used to solve the equations, and the results can be
223 presented in tabular format. The simplex method finds the optimized allocation after
224 iterations of integrating each decision variable one by one into the allocation process. The
225 decision variable with the greatest influence on the outcome variable is selected first, and the
226 next iteration uses the next most influential decision variable.

227 Linear programs that include variables with integers instead of continuous values may pose
228 problems in finding appropriate allocations when using the simplex method. Different
229 alternative methods have been proposed to ensure an allocation is possible. One method
230 includes solving the integer, linear program as a continuous, linear program using the simplex
231 method then rounding the non-integer allocation. However, the optimal allocation to the
232 continuous linear programming model with rounded allocation is not guaranteed to be
233 optimal or even to be feasible. With today's computing power, the "branch-and-bound"
234 approach (Sarker et al., 2008) can be used to solve an integer linear program to optimality.
235 However, if the number of potential allocations is large (> 20), computation time can be
236 extensive or the optimal allocation may not be able to be found in a reasonable amount of
237 time.

238 If complex optimization models with more than one objective to be reached or with multiple
239 decision variables and many constraints or that have nonlinear/dynamic features are
240 constructed, it will be difficult to reach exact allocation. In these situations, heuristic
241 approaches that apply more sophisticated analysis methods such as neural networking, fuzzy
242 logic, genetic algorithms, etc. will be chosen to solve the problem. Under such circumstances
243 it will be important to check the validity of the allocations proposed by those sophisticated
244 analyses methods. Expert advice in those matters will be more than welcome to better
245 develop an appropriate analysis plan (Gilli et al, 2003, Wenker et al, 2004).

246 **Uncertainty Analyses**

247 When solving continuous, linear constrained optimization models using the simplex method
248 via an available software package, a form of sensitivity analysis is outputted along with the
249 results (Earnshaw et al., 2003). Specifically, the solution output provides us with conditions

250 around the objective function coefficients under which decision variables will remain and
251 become part of the optimal allocation. This includes the range over which the objective
252 function coefficients for specific decision variables may change while the current allocation
253 remains optimal or how the objective function coefficients of a specific decision variable
254 (reduced cost) must change in order for this decision variable to be part of the allocation.
255 Change in the limits set on constraints is also presented as one can understand the range over
256 which this limit can vary such that the current allocation stays optimal. Slack or surplus can
257 indicate how much of the constraint limit is still available to be used. Shadow prices are
258 helpful for understanding to what extent an increase of one more unit of a constraint's limit
259 will improve the outcome of the objective function.
260 Like other modeling exercises, univariate analyses for specific variables and parameters or
261 specific scenarios can be developed as well. Stochastic methods could also be applied.
262 However, they are less well defined. Specifically, development of a full analysis with
263 stochastic instead of deterministic values is limited. Research continues to identify how to
264 apply these methods in optimization (Tanner et al., 2008).

265 **Validation**

266 The validation process should include a check of the reliability of the data sources,
267 assumptions made in the model construct and subsequent results, and whether the disease
268 model used to generate some of the data inputs in the optimization model (e.g. the impact of
269 the vaccination program or other interventions on the outcomes of the objective function) fits
270 the observed disease outcomes. It is also critical that the optimal combination of interventions
271 identified by the CO meets any feasibility constraints and that their total cost is within the
272 budget limit. The accuracy of the coding should also be evaluated.

273 The dual formulation (maximization or minimization of alternative objectives) facilitates the
274 validation of a CO analysis. When this process is used, the results for the combination of
275 interventions selected should be the same for both objectives (Sarker and Newton, 2008).

276 **Transparency**

277 Constrained optimization modeling is highly formulaic/mathematical in nature. Thus, a way
278 to increase transparency is to present a layman's description of the decision variables,
279 objective function, and constraints along with the formulation. Transparency is also increased
280 when the number of decision variables and constraints are limited. As the number of decision
281 variables and constraints in the equations increase or multiple or nonlinear objective
282 functions are used instead of linear relationships (Tanner et al., 2008), the formulation can
283 then be more difficult to follow.

284 **Software Options**

285 Many software options exist for CO, such as Solver in Microsoft Excel and standalone
286 analysis tools for professionals. Which program to use depends on its price, the objective for
287 using the software, the availability of technical support, the flexibility needed, its ability to
288 handle many constraints and decision variables, how often the modeling approach is used,
289 and whether extended sensitivity analysis is needed. The following websites describe
290 programs available for CO:

- 291 ■ Optimizely (www.optimizely.com)
- 292 ■ AIMMS Prescriptive Analytics Platform (Aimms.com)

293 ▪ O.R. & Analytics (www.informs.org)

294 **Reporting**

295 The Consolidated Health Economic Evaluation Reporting Standards should be used to report
296 the results of all health economic analyses (Husereau et al., 2013). The question to answer
297 must be specified in the report, as must the reasons for selecting the method used because
298 many people might not be familiar with CO. The methodology section of the report needs to
299 describe the objective function, decision variables, and constraints used as well as the
300 perspective of the analysis (e.g. whether the perspective is that of one decision maker, the
301 budget holder, or more than one decision maker). The sensitivity analysis should include
302 scenario analyses as well as one-way or multi-way analyses so that readers can understand
303 which input values have the most impact on the results.

304 The results section may include a graphical presentation if feasible, but it is unlikely when the
305 optimization model is allocating among more than three interventions (i.e., decision
306 variables). A tabular format will then be the main presentation form of the results. Finally, the
307 discussion section should highlight why the selected method is a good approach for the
308 problem to be analyzed, as stated in the introduction.

309 **Strengths and Limitations of CO**

310 CO modeling cannot be used in all conditions, but it does provide flexibility for assessing the
311 ability to use a combination of different interventions to achieve a given objective (e.g.,
312 screening programs with different recall frequencies for early detection of cervical cancer). It
313 also allows constraints to be included that are not necessarily quantifiable in other modeling
314 approaches but can be measured qualitatively, such as by ethical and or equity considerations
315 (Stinnett et al., 1996).

316 Constrained optimization modeling is a system of equations that can be graphically plotted in
317 mathematical planes. However, once more than three decision variables are in the equations,
318 it becomes challenging to present graphically the problem and the optimal allocations.

319 Also as problems grow in number of decision variables and constraints, solving to optimality
320 will become more challenging. But with today's computing power, optimization software is
321 able to facilitate the search for allocations.

322 Meanwhile, what makes constrained optimization modeling most attractive is the direct link
323 between the availability of a budget and a health goal to be reached. When different options
324 are available for reaching a certain objective, solving such a problem will enable one to
325 understand the degree to which a new vaccination program should be used instead of or in
326 addition to other available intervention while meeting budget and other constraints. The
327 interconnections between the different interventions to be combined for reaching a health
328 objective makes the price setting of each more transparent related to the budget constraint. It
329 helps to prioritize the new and current interventions and promote a budget plan over several
330 years.

331 **References**

- 332 Becker NG, Starczak DN. Optimal vaccination strategies for a community of households.
333 Math Biosci. 1997 Jan 15;139:117-32.
- 334 Buongiorno J, Gilles K. Decision methods for forest resource management. 1st ed. Academic
335 Press, Elsevier Science; 2003.
- 336 Crown W, Buykkaramikii N, Thokala P, Morton A, Sir M, et al. Constrained optimization
337 methods in health services research – an introduction: report 1 of the ISPOR Optimization
338 Methods Emerging Good Practices Task Force. Value in Health. 2017;20:310-319.
- 339 Demarteau N, Breuer T, Standaert B. Selecting a mix of prevention strategies against cervical
340 cancer for maximum efficiency with an optimization program. Pharmacoeconomics. 2012
341 Apr;30:337-53.
- 342 Demarteau N, Morhason-Belo IO, Akinwunmi B, Adewole IF. Modeling optimal cervical
343 cancer prevention strategies in Nigeria. BMC Cancer. 2014; 14: 365.
- 344 Dixit A. Optimization in Economic Theory. 2nd ed. Oxford: Oxford University Press; 1990.
- 345 Earnshaw SR, Dennett SL. Integer/linear mathematical programming models: a tool for
346 allocating healthcare resources. Pharmacoeconomics. 2003;21:839-51.
- 347 Gilli, M., Winker, P. A Global Optimization Heuristic for Estimating Agent Based Models.
348 Computational Statistics and Data Analysis, 2003, 42, 299–312
- 349 Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, et al.
350 Consolidated Health Economic Evaluation Reporting Standards (CHEERS) – explanation
351 and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guideline
352 Good Reporting Practices Task Force. Value Health. 2013;16:231-50.
- 353 IOM (Institute of Medicine). Ranking vaccines: a prioritization framework: phase I:
354 demonstration of concept and a software blueprint. Washington, DC: The National
355 Academies Press; 2012.
- 356 Madhavan G, Kinpritma S. Ranking vaccines, a prioritization framework. 1st ed.
357 Washington, D.C.: The National Academies Press; 2012.
- 358 Madhavan G, Sangha K, Phelps C, Fryback D, et al. Ranking vaccines. A prioritization
359 software tool. 1st ed. Washington, D.C.: The National Academies Press; 2013.
- 360 Murty K. Linear programming. New York: John Wiley & Sons, Inc; 1983.
- 361 Petrou S, Wolstenholme J. A review of alternative approaches to healthcare resource
362 allocation. Pharmacoeconomics. 2000 Jul;18:33-43.
- 363 Sanders JL. Quantitative guidelines for communicable disease control programs. Biometrics.
364 1971 Dec;27:883-93.
- 365 Sarker RA, Newton ChS. Optimization modeling, a practical approach. 1st ed. CRC Press;
366 2008.

- 367 Sethi SP. Quantitative guidelines for communicable disease control program: a complete
368 synthesis. *Biometrics*. 1974 Dec; 30:681-91.
- 369 Standaert B, Schecroun N, Ethgen O, et al. Optimising the introduction of multiple childhood
370 vaccines in Japan: a model proposing the introduction sequence achieving the highest health
371 gains. *Health Policy*, 2017 Dec; 121(12): 1303-1312.
- 372 Stinnett AA, Paltiel AD. Mathematical programming for the efficient allocation of health care
373 resources. *J Health Econ*. 1996 Oct;15:641-53.
- 374 Tanner MW, Sattenspiel L, Ntaimo L. Finding optimal vaccination strategies under parameter
375 uncertainty using stochastic programming. *Math Biosci*. 2008 Oct;215:144-51.
- 376 Walker P, Griffin J, Ferguson N, Ghani A. Estimating the most efficient allocation of
377 interventions to achieve reductions in *Plasmodium falciparum* malaria burden and
378 transmission in Africa: a modeling study. *Lancet Glob Health*. 2016;4:e474-84.
- 379 Winker, P., Gilli, M. Applications of optimization heuristics to estimation and modelling problems.
380 *Computational Statistics & Data Analysis*. 2004, 47, 211–223.
- 381 Weniger BG, Chen RT, Jacobson SH, Sewell EC, Deuson R, Livengood JR, et al. Addressing
382 the challenges to immunization practice with an economic algorithm for vaccine selection.
383 *Vaccine*. 1998 Nov;16:1885-97.